Incyte Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Incyte Corporation - Product Pipeline Review - 2016', provides an overview of the Incyte Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Incyte Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Incyte Corporation - The report provides overview of Incyte Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Incyte Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Incyte Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Incyte Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Incyte Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Incyte Corporation Snapshot 6 Incyte Corporation Overview 6 Key Information 6 Key Facts 6 Incyte Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Incyte Corporation - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Combination Treatment Modalities 15 Pipeline Products - Partnered Products 16 Partnered Products/Combination Treatment Modalities 17 Pipeline Products - Out-Licensed Products 18 Out-Licensed Products/Combination Treatment Modalities 19 Incyte Corporation - Pipeline Products Glance 20 Incyte Corporation - Clinical Stage Pipeline Products 20 Phase II Products/Combination Treatment Modalities 20 Phase I Products/Combination Treatment Modalities 21 Incyte Corporation - Early Stage Pipeline Products 22 IND/CTA Filed Products/Combination Treatment Modalities 22 Preclinical Products/Combination Treatment Modalities 23 Discovery Products/Combination Treatment Modalities 24 Incyte Corporation - Drug Profiles 25 (INCB-039110 + INCB-040093) 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 epacadostat 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 INCB-40093 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 itacitinib adipate 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ruxolitinib phosphate 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 INCB-50465 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 INCB-52793 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 INCB-53914 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 INCB-54329 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 INCB-54828 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 INCB-59872 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 SHR-1210 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 INCAGN-1876 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 INCAGN-1949 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 INCB-57643 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Monoclonal Antibody to Inhibit LAG3 for Oncology 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Monoclonal Antibody to Inhibit TIM3 for Oncology 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule for Oncology 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules for Chronic Inflammation 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Incyte Corporation - Pipeline Analysis 52 Incyte Corporation - Pipeline Products by Target 52 Incyte Corporation - Pipeline Products by Route of Administration 54 Incyte Corporation - Pipeline Products by Molecule Type 55 Incyte Corporation - Pipeline Products by Mechanism of Action 56 Incyte Corporation - Recent Pipeline Updates 58 Incyte Corporation - Dormant Projects 75 Incyte Corporation - Discontinued Pipeline Products 76 Discontinued Pipeline Product Profiles 76 aderbasib 76 INCB-047986 76 itacitinib adipate 76 ruxolitinib phosphate 76 Incyte Corporation - Company Statement 78 Incyte Corporation - Locations And Subsidiaries 82 Head Office 82 Other Locations & Subsidiaries 82 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
List of Tables
Incyte Corporation, Key Information 6 Incyte Corporation, Key Facts 6 Incyte Corporation - Pipeline by Indication, 2016 8 Incyte Corporation - Pipeline by Stage of Development, 2016 13 Incyte Corporation - Monotherapy Products in Pipeline, 2016 14 Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016 15 Incyte Corporation - Partnered Products in Pipeline, 2016 16 Incyte Corporation - Partnered Products/ Combination Treatment Modalities, 2016 17 Incyte Corporation - Out-Licensed Products in Pipeline, 2016 18 Incyte Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 19 Incyte Corporation - Phase II, 2016 20 Incyte Corporation - Phase I, 2016 21 Incyte Corporation - IND/CTA Filed, 2016 22 Incyte Corporation - Preclinical, 2016 23 Incyte Corporation - Discovery, 2016 24 Incyte Corporation - Pipeline by Target, 2016 53 Incyte Corporation - Pipeline by Route of Administration, 2016 54 Incyte Corporation - Pipeline by Molecule Type, 2016 55 Incyte Corporation - Pipeline Products by Mechanism of Action, 2016 56 Incyte Corporation - Recent Pipeline Updates, 2016 58 Incyte Corporation - Dormant Developmental Projects,2016 75 Incyte Corporation - Discontinued Pipeline Products, 2016 76 Incyte Corporation, Subsidiaries 82
List of Figures
Incyte Corporation - Pipeline by Top 10 Indication, 2016 8 Incyte Corporation - Pipeline by Stage of Development, 2016 13 Incyte Corporation - Monotherapy Products in Pipeline, 2016 14 Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016 15 Incyte Corporation - Partnered Products in Pipeline, 2016 16 Incyte Corporation - Out-Licensed Products in Pipeline, 2016 18 Incyte Corporation - Pipeline by Top 10 Target, 2016 52 Incyte Corporation - Pipeline by Route of Administration, 2016 54 Incyte Corporation - Pipeline by Molecule Type, 2016 55 Incyte Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016 56
Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiencyRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance drivRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.